vs
Side-by-side financial comparison of BrightSpire Capital, Inc. (BRSP) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
BrightSpire Capital, Inc. is the larger business by last-quarter revenue ($83.2M vs $70.6M, roughly 1.2× Viridian Therapeutics, Inc.\DE). BrightSpire Capital, Inc. runs the higher net margin — -17.3% vs -49.0%, a 31.8% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -0.4%). BrightSpire Capital, Inc. produced more free cash flow last quarter ($55.1M vs $-84.7M).
Oakley Capital Investments, is a large British investment trust focused on investments in mid-market companies in the business services, consumer, education and technology sectors. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
BRSP vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.2M | $70.6M |
| Net Profit | $-14.4M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | — | -56.7% |
| Net Margin | -17.3% | -49.0% |
| Revenue YoY | -0.4% | 81958.1% |
| Net Profit YoY | 27.3% | 54.9% |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $83.2M | — | ||
| Q3 25 | $83.9M | $70.6M | ||
| Q2 25 | $85.9M | — | ||
| Q1 25 | $77.6M | — | ||
| Q4 24 | $83.5M | — | ||
| Q3 24 | $88.2M | — | ||
| Q2 24 | $91.4M | — | ||
| Q1 24 | $95.8M | — |
| Q4 25 | $-14.4M | — | ||
| Q3 25 | $984.0K | $-34.6M | ||
| Q2 25 | $-23.1M | — | ||
| Q1 25 | $5.3M | — | ||
| Q4 24 | $-19.7M | — | ||
| Q3 24 | $12.7M | — | ||
| Q2 24 | $-67.9M | — | ||
| Q1 24 | $-57.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | -1.7% | -56.7% | ||
| Q2 25 | -54.5% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | -24.9% | — | ||
| Q3 24 | 13.2% | — | ||
| Q2 24 | -74.9% | — | ||
| Q1 24 | -59.4% | — |
| Q4 25 | -17.3% | — | ||
| Q3 25 | 1.2% | -49.0% | ||
| Q2 25 | -26.9% | — | ||
| Q1 25 | 6.9% | — | ||
| Q4 24 | -23.7% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | -74.2% | — | ||
| Q1 24 | -59.6% | — |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.19 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.16 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $-0.53 | — | ||
| Q1 24 | $-0.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.8M | $490.9M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $938.4M | $503.0M |
| Total Assets | $3.6B | $577.1M |
| Debt / EquityLower = less leverage | 2.63× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.8M | — | ||
| Q3 25 | $113.4M | $490.9M | ||
| Q2 25 | $154.3M | — | ||
| Q1 25 | $200.9M | — | ||
| Q4 24 | $302.2M | — | ||
| Q3 24 | $263.8M | — | ||
| Q2 24 | $203.3M | — | ||
| Q1 24 | $221.5M | — |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $938.4M | — | ||
| Q3 25 | $976.4M | $503.0M | ||
| Q2 25 | $994.4M | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $3.6B | — | ||
| Q3 25 | $3.3B | $577.1M | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.6B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.8B | — | ||
| Q2 24 | $3.8B | — | ||
| Q1 24 | $3.9B | — |
| Q4 25 | 2.63× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 2.27× | — | ||
| Q1 25 | 2.27× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 2.28× | — | ||
| Q1 24 | 2.17× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.0M | $-84.6M |
| Free Cash FlowOCF − Capex | $55.1M | $-84.7M |
| FCF MarginFCF / Revenue | 66.2% | -120.1% |
| Capex IntensityCapex / Revenue | 21.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $102.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.0M | — | ||
| Q3 25 | $29.9M | $-84.6M | ||
| Q2 25 | $17.4M | — | ||
| Q1 25 | $10.5M | — | ||
| Q4 24 | $103.4M | — | ||
| Q3 24 | $31.3M | — | ||
| Q2 24 | $22.9M | — | ||
| Q1 24 | $24.6M | — |
| Q4 25 | $55.1M | — | ||
| Q3 25 | $27.4M | $-84.7M | ||
| Q2 25 | $11.6M | — | ||
| Q1 25 | $8.0M | — | ||
| Q4 24 | $97.3M | — | ||
| Q3 24 | $28.3M | — | ||
| Q2 24 | $22.7M | — | ||
| Q1 24 | $22.2M | — |
| Q4 25 | 66.2% | — | ||
| Q3 25 | 32.7% | -120.1% | ||
| Q2 25 | 13.4% | — | ||
| Q1 25 | 10.3% | — | ||
| Q4 24 | 116.6% | — | ||
| Q3 24 | 32.1% | — | ||
| Q2 24 | 24.9% | — | ||
| Q1 24 | 23.2% | — |
| Q4 25 | 21.6% | — | ||
| Q3 25 | 2.9% | 0.2% | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 3.2% | — | ||
| Q4 24 | 7.3% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | 30.36× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.97× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.46× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
